JP2024538839A5 - - Google Patents

Info

Publication number
JP2024538839A5
JP2024538839A5 JP2024529656A JP2024529656A JP2024538839A5 JP 2024538839 A5 JP2024538839 A5 JP 2024538839A5 JP 2024529656 A JP2024529656 A JP 2024529656A JP 2024529656 A JP2024529656 A JP 2024529656A JP 2024538839 A5 JP2024538839 A5 JP 2024538839A5
Authority
JP
Japan
Prior art keywords
subject
composition according
cells
composition
mesenchymal progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538839A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080089 external-priority patent/WO2023092043A1/en
Publication of JP2024538839A publication Critical patent/JP2024538839A/ja
Publication of JP2024538839A5 publication Critical patent/JP2024538839A5/ja
Pending legal-status Critical Current

Links

JP2024529656A 2021-11-17 2022-11-17 転帰不良のリスクが高い対象における進行性心不全の治療方法 Pending JP2024538839A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2021903706 2021-11-17
AU2021903706A AU2021903706A0 (en) 2021-11-17 Method of treating progressive heart failure in subjects at high risk of poor outcomes
US202263384200P 2022-11-17 2022-11-17
US63/384,200 2022-11-17
PCT/US2022/080089 WO2023092043A1 (en) 2021-11-17 2022-11-17 Method of treating progressive heart failure in subjects at high risk of poor outcomes

Publications (2)

Publication Number Publication Date
JP2024538839A JP2024538839A (ja) 2024-10-23
JP2024538839A5 true JP2024538839A5 (enExample) 2025-11-28

Family

ID=84767093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529656A Pending JP2024538839A (ja) 2021-11-17 2022-11-17 転帰不良のリスクが高い対象における進行性心不全の治療方法

Country Status (6)

Country Link
US (1) US20250090589A1 (enExample)
JP (1) JP2024538839A (enExample)
KR (1) KR20240115826A (enExample)
AU (1) AU2022394471A1 (enExample)
CA (1) CA3238314A1 (enExample)
WO (1) WO2023092043A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
CA3247653A1 (en) * 2014-12-23 2025-10-31 Mesoblast International Sarl Method for treating heart failure

Similar Documents

Publication Publication Date Title
Zhang et al. A collagen hydrogel loaded with HDAC7-derived peptide promotes the regeneration of infarcted myocardium with functional improvement in a rodent model
Ohnishi et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis
Aguilar et al. New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
US9226978B2 (en) Method of treating ischemic disorders
US20120014920A1 (en) Annexin and its use to treat inflammatory disorders
He et al. Activation mechanisms and multifaceted effects of mast cells in ischemia reperfusion injury
Beiert et al. Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties
JP2024500698A5 (enExample)
JP2018538367A (ja) ホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)の心臓疾患を治療するための標的設定
JP2023529502A5 (enExample)
Wang et al. The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives
Roubille et al. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials
Zisa et al. Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair
Nakamura et al. The effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction
US9974831B2 (en) Methods of reducing myocardial injury following myocardial infarction
Sun et al. Modified bFGF targeting connective tissue growth factor in the injured microenvironment improved cardiac repair after chronic myocardial ischemia
WO2005049062A1 (en) Use of g-csf for treating ischemia
Rosenberg et al. Rapid progressive eosinophilic cardiomyopathy in a patient with Churg–Strauss syndrome (CSS)
Orabi et al. Molecular and clinical roles of incretin-based drugs in patients with heart failure
Damayanti et al. Mesenchymal Stem Cells Role in COVID-19 Myocardial Injury
Baka et al. Ivabradine in the management of COVID-19-related cardiovascular complications: a perspective
JP2023170339A (ja) 拡張型心筋症を処置または予防するための医薬組成物
Karaman et al. Torsade de Pointes Following Myocarditis; A Case Report
Wang et al. Severe Myocarditis Caused by XELOX Chemotherapy After Rectal Cancer Surgery: A Case Report
Horio et al. Bio-molecular markers for cardiovascular disease: significance of natriuretic peptides and adrenomedullin